Latest Commercialisation News

Universal Biosensors reported a 28% increase in customer receipts to $1.6 million for Q1 2025, alongside improved cash flow and plans for a new product launch later this year.

Elevate Uranium Ltd reports steady progress on its U-pgrade demonstration plant and ongoing exploration drilling at Koppies and Marenica projects, alongside a 12% resource increase at the Bigrlyi Joint Venture and the appointment of a new chairman.

Orbital Corporation Ltd reported a positive operating cash flow of $0.7 million for Q1 2025, supported by a solid order book and ongoing development of a new larger capacity engine prototype.

Opyl Limited reports strong progress in AI-driven clinical trial optimisation with active commercial initiatives, strategic partnerships, and a planned capital raise to support growth amid tight cash reserves.

SportsHero Limited has made significant strides in commercialising its iGV Family Game Pass, securing key partnerships with major Southeast Asian telecom operators and expanding its market footprint to the Philippines.

Paradigm Biopharmaceuticals has secured ethics approval and appointed a CRO to launch its global phase 3 trial for injectable Pentosan Polysulfate Sodium in knee osteoarthritis, while initiating a substantial capital raising program.

Andromeda Metals has entered exclusive negotiations for a $75 million debt facility to fund the Stage 1A+ development of its Great White Project, alongside operational progress and exploration drilling.

Zelira Therapeutics has enhanced its financial flexibility through a $1.15 million R&D tax refund and a $1 million At-the-Market equity facility, while progressing FDA trial preparations for its HOPE® 1 autism treatment.

NuEnergy Gas Limited has initiated drilling site preparation at its Tanjung Enim PSC, progressing towards early gas sales, while securing key commercial agreements and maintaining a strong cash position.

ReNerve Limited reported a 39% sales increase in Q3 FY25 alongside compelling clinical validation of its NervAlign® Nerve Cuff and strategic international partnerships, positioning the company for broader market penetration.

InteliCare Holdings has secured a binding agreement to trial its AI-driven platform at mecwacare’s Trescowthick Centre, marking a significant step in its commercialisation strategy within Victoria’s aged care sector.

IDT Australia reports a robust 30% jump in quarterly revenue to $4.1 million, driven by strong contract wins and a $62 million pipeline of open proposals, signaling sustained growth in pharmaceutical manufacturing.